A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors
Clinical trial NCT07512063 · COMPLETED
Trial details
- NCT number
- NCT07512063
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2024-10-08
- Primary completion
- 2025-03-17
- Enrollment
- 480
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.